Customer Spotlight

Genovac on Antibody Discovery

genovac-logo

The three targets used in this work exhibit common challenges encountered in difficult targets:

  • Small extracellular regions that limit the number of antigenic epitopes
  • High sequence homology that reduces the chances of eliciting an immune response
  • Poor cell surface expression that makes cell-based screening difficult
inline-graph (1)
CUSTOMER QUOTE
“The throughput of two Beacon systems, coupled with our genetic immunization technology, has increased the probability of campaign success by delivering 10-fold more lead candidates against difficult targets like GPCRs.”

Brian Walters, CEO of Genovac

FINDING THE NEEDLE IN THE HAYSTACK

Traditional hybridoma and phage display methods have shown limited success in delivering therapeutic antibodies against promising but difficult targets such as GPCRs and ion channels. Genovac is a contract research organization that is committed to get the right antibodies in the shortest amount of time. To accomplish this, they offer a powerful genetic immunization technology coupled with the Beacon® optofluidic system to screen the B cell repertoire from mice and rats (with rabbit and alpaca platforms under development), providing access to greater biodiversity than traditional approaches.

Explore Customer Spotlights

Customer Spotlight
MYCENAX: Developing the Next-Gen Cell Line Development Platform with Bruker Cellular Analysis
Customer Spotlight
Medical College of Wisconsin on T Cell Characterization
Customer Spotlight
Catalent Biologics on Cell Line Development
Customer Spotlight
Abveris on Antibody Discovery
Customer Spotlight
Amgen on Antibody Discovery and Cell Line Development